Cipla Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1mc45enfn5pc4qcx3hymri5t.pdf

Key Takeaways


The Revlimid Cliff and Margin Reset

Ashish Adukia: "It will be lower profitability than Revlimid and it also depends on, by the way, on timing. So, when you launch a system collectively, I am saying that it will make up, it will be lower profitability, but important to note is that our respiratory assets are all in-house. So, they will come at a very good gross margin."

Lanreotide: The Supply Shock

Ashish Adukia: "No, there has been no adjustment in the inventory that we have had on account of Lanreotide. Whatever we have sold in this quarter of Lanreotide, a normal material cost against that is what is booked."

The Pipeline: Respiratory and Peptides

Umang Vohra: "What I was trying to say is that it's quite likely that one, if not both, could be one of the largest products for the Company."

India and EMEU: The Steady Engines

Achin Gupta: "From CIPLA perspective, we do not have much or any impact because we are already at or better than the standards that are asked for."

Regional and Base Business Dynamics


Guidance & Commitments

CommitmentSpecificsTimeline
FY26 EBITDA marginLand at around 21%FY26 full year
Lanreotide resupplyResume from existing site subject to USFDA clearanceH1 FY27
Respiratory launchesTwo big plus one smaller (Advair) launchNext 6 months
Respiratory launchAnother big respiratory launch (likely Symbicort)6-12 months
Peptide launchesThree peptide assets, none from Pharmathen facilityFY27
Generic Victoza launchApproval received, launch expectedDuring the quarter
South Africa primary revenueNormalization expectedNext quarter
US $1 bn revenue guidanceWill be revised downward (Lanreotide absent from Q4)FY27 target
R&D spendTry to keep around 6% of sales, with quarterly lumpinessOngoing
FY27 margin and revenue guidanceTo be provided after annual operating plan is finalizedNext quarter
Cost optimization programSome benefit towards end of this year, full-year benefits next yearFY27

Key Metrics

MetricQ3 FY26
Revenue₹7,074 cr, flat YoY
EBITDA margin (excl. other income)17.7%, decline driven by lower generic Revlimid revenues
Gross margin after material cost62.8%, decline driven by lenalidomide drop and product mix
Profit after tax₹676 cr, 9.6% of sales; includes one-time labour code impact of ₹276 cr in exceptional items
Total expenses₹3,187 cr, +13% YoY on planned R&D, manufacturing, and talent investments
R&D investments₹494 cr, 7.0% of revenue, +37.4% YoY
Effective tax rate24.5%
Net cash balance₹10,229 cr as of Dec 31, 2025, after dividend and Galvus payment; debt incl. lease liabilities ₹489 cr
FY26 EBITDA margin guidance~21%, lowered from prior expectation; Q3 EBITDA was 1.5%–2% below internal plan
One-India business growth10% YoY
Branded prescription growth10% YoY
Chronic mix62.3% YoY
Respiratory therapy growth11% YoY, outperformed IPM therapy growth by 400 bps (IQVIA quarter ended Dec '25)
Anti-diabetes and cardiac growth13% each YoY
Urology growth15% YoY
North America quarterly revenue$167 million, includes small Lenalidomide contribution; base business ex-Lena grew double-digit YoY
U.S. Albuterol MDI market share22%, number one position (IQVIA week ending Dec 26, 2025)
South Africa private market secondary growth6.3%, outperformed market growth of 5.7% (IQVIA MAT Nov '25)
EMEU quarterly revenueAbove $100 million for fourth successive quarter, +7% YoY in USD terms
Brands in INR 100+ crore club30 brands, 4 added this quarter
Brands in IPM top 30022 brands
Trade generics new launches8 new launches in the quarter
Lanreotide supply statusProduction temporarily paused after partner Pharmathen received 9 USFDA 483 observations; resupply expected H1 FY27
Galvus perpetual rights payment₹1,100 cr paid to Novartis, sitting in intangibles/capital advances